Cargando…
NAD(+) and Vascular Dysfunction: From Mechanisms to Therapeutic Opportunities
Nicotinamide adenine dinucleotide (NAD(+)) is an essential and pleiotropic coenzyme involved not only in cellular energy metabolism, but also in cell signaling, epigenetic regulation, and post-translational protein modifications. Vascular disease risk factors are associated with aberrant NAD(+) meta...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Lipidology and Atherosclerosis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133775/ https://www.ncbi.nlm.nih.gov/pubmed/35656147 http://dx.doi.org/10.12997/jla.2022.11.2.111 |
_version_ | 1784713645063667712 |
---|---|
author | Abdellatif, Mahmoud Bugger, Heiko Kroemer, Guido Sedej, Simon |
author_facet | Abdellatif, Mahmoud Bugger, Heiko Kroemer, Guido Sedej, Simon |
author_sort | Abdellatif, Mahmoud |
collection | PubMed |
description | Nicotinamide adenine dinucleotide (NAD(+)) is an essential and pleiotropic coenzyme involved not only in cellular energy metabolism, but also in cell signaling, epigenetic regulation, and post-translational protein modifications. Vascular disease risk factors are associated with aberrant NAD(+) metabolism. Conversely, the therapeutic increase of NAD(+) levels through the administration of NAD(+) precursors or inhibitors of NAD(+)-consuming enzymes reduces chronic low-grade inflammation, reactivates autophagy and mitochondrial biogenesis, and enhances oxidative metabolism in vascular cells of humans and rodents with vascular pathologies. As such, NAD(+) has emerged as a potential target for combatting age-related cardiovascular and cerebrovascular disorders. This review discusses NAD(+)-regulated mechanisms critical for vascular health and summarizes new advances in NAD(+) research directly related to vascular aging and disease, including hypertension, atherosclerosis, coronary artery disease, and aortic aneurysms. Finally, we enumerate challenges and opportunities for NAD(+) repletion therapy while anticipating the future of this exciting research field, which will have a major impact on vascular medicine. |
format | Online Article Text |
id | pubmed-9133775 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Korean Society of Lipidology and Atherosclerosis |
record_format | MEDLINE/PubMed |
spelling | pubmed-91337752022-06-01 NAD(+) and Vascular Dysfunction: From Mechanisms to Therapeutic Opportunities Abdellatif, Mahmoud Bugger, Heiko Kroemer, Guido Sedej, Simon J Lipid Atheroscler Review Nicotinamide adenine dinucleotide (NAD(+)) is an essential and pleiotropic coenzyme involved not only in cellular energy metabolism, but also in cell signaling, epigenetic regulation, and post-translational protein modifications. Vascular disease risk factors are associated with aberrant NAD(+) metabolism. Conversely, the therapeutic increase of NAD(+) levels through the administration of NAD(+) precursors or inhibitors of NAD(+)-consuming enzymes reduces chronic low-grade inflammation, reactivates autophagy and mitochondrial biogenesis, and enhances oxidative metabolism in vascular cells of humans and rodents with vascular pathologies. As such, NAD(+) has emerged as a potential target for combatting age-related cardiovascular and cerebrovascular disorders. This review discusses NAD(+)-regulated mechanisms critical for vascular health and summarizes new advances in NAD(+) research directly related to vascular aging and disease, including hypertension, atherosclerosis, coronary artery disease, and aortic aneurysms. Finally, we enumerate challenges and opportunities for NAD(+) repletion therapy while anticipating the future of this exciting research field, which will have a major impact on vascular medicine. Korean Society of Lipidology and Atherosclerosis 2022-05 2022-04-06 /pmc/articles/PMC9133775/ /pubmed/35656147 http://dx.doi.org/10.12997/jla.2022.11.2.111 Text en Copyright © 2022 The Korean Society of Lipid and Atherosclerosis. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Abdellatif, Mahmoud Bugger, Heiko Kroemer, Guido Sedej, Simon NAD(+) and Vascular Dysfunction: From Mechanisms to Therapeutic Opportunities |
title | NAD(+) and Vascular Dysfunction: From Mechanisms to Therapeutic Opportunities |
title_full | NAD(+) and Vascular Dysfunction: From Mechanisms to Therapeutic Opportunities |
title_fullStr | NAD(+) and Vascular Dysfunction: From Mechanisms to Therapeutic Opportunities |
title_full_unstemmed | NAD(+) and Vascular Dysfunction: From Mechanisms to Therapeutic Opportunities |
title_short | NAD(+) and Vascular Dysfunction: From Mechanisms to Therapeutic Opportunities |
title_sort | nad(+) and vascular dysfunction: from mechanisms to therapeutic opportunities |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133775/ https://www.ncbi.nlm.nih.gov/pubmed/35656147 http://dx.doi.org/10.12997/jla.2022.11.2.111 |
work_keys_str_mv | AT abdellatifmahmoud nadandvasculardysfunctionfrommechanismstotherapeuticopportunities AT buggerheiko nadandvasculardysfunctionfrommechanismstotherapeuticopportunities AT kroemerguido nadandvasculardysfunctionfrommechanismstotherapeuticopportunities AT sedejsimon nadandvasculardysfunctionfrommechanismstotherapeuticopportunities |